# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down fro...
Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Buy and lowers the price target from $204 to $178.
Barclays analyst Gena Wang maintains Moderna (NASDAQ:MRNA) with a Overweight and lowers the price target from $168 to $155.
Piper Sandler analyst Edward Tenthoff reiterates Moderna (NASDAQ:MRNA) with a Overweight and lowers the price target from $2...
Moderna's vaccine magic is slowly losing its charm, as evidenced by the warning the company issued on Thursday but Ark repo...
The CNN Fear and Greed index fell to 39.6, signaling Fear in the market. Dow Jones dropped 495 points, Nasdaq down 2.3%, S&...
Needham analyst Joseph Stringer reiterates Moderna (NASDAQ:MRNA) with a Hold.
Shares of Moderna (MRNA) have broken an important support level. This means a new downtrend may be forming.